Entries |
Document | Title | Date |
20080233155 | Compositions For Antigen-Specific Induction of Tolerance - The invention relates to an immunogenic composition for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance. | 09-25-2008 |
20080254071 | Homeopathic composition for alleviating allergy symptoms - The present invention is directed towards a homeopathically designed composition comprising effective amounts of | 10-16-2008 |
20080286311 | Protein Allergen Derivatives - The present invention relates to a method for producing derivatives of wild-type protein allergens with reduced allergenic activity, characterized in by the following steps: providing a wild-type protein allergen with an allergenic activity, splicing said wild-type protein allergen into two parts, said two parts having a reduced allergenic activity or lacking allergenic activity and rejoining said two fragments in inverse orientation; as well as allergen derivatives. | 11-20-2008 |
20090017075 | Immunomodulatory compositions, methods of making, and methods of use thereof - The invention relates to new immunomodulatory compositions which comprise a cationic condensing agent, an immunomodulatory compound, and a stabilizing agent. The compositions of the invention typically form particles which have increased immunomodulatory activity as compared to immunomodulatory compounds not formulated in the compositions of the invention. Also provided are methods of making the compositions and methods for therapeutic use of the compositions. | 01-15-2009 |
20090068233 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND IMMUNOTHERAPY OF POLLEN ALLERGY - A diagnostic pollen array includes allergens extracted from pollen coat material. Diagnostic pollen arrays are useful to diagnose allergy in individuals, identify novel allergens, identify genetic loci responsible for allergy in hosts, and to develop treatment plans for allergy. | 03-12-2009 |
20090098167 | PHL P 1 Allergen Derivative - Method for producing derivatives of wild-type protein allergen Phl p 1 with reduced allergenic activity compared to the wild-type allergen, comprising the following steps: providing wild-type protein allergen Phl p 1, fragmenting said wild-type protein allergen into at least three fragments, wherein at least one fragment of said at least three fragments comprises at least one T-cell epitope and said at least three fragments have a reduced allergenic activity or lack allergenic activity and rejoining said at least three fragments in an order differing from the order of the fragments in the wild-type allergen. | 04-16-2009 |
20090110701 | T-CELL MODULATION - The invention provides methods and materials for use in modulating T cell activation, based on the production and secretion of soluble cytotoxic T-lymphocyte antigen-4 (sCTLA-4) by cells of the immune system. The method involves stimulating secretion of endogenous sCTLA-4 by T cells, which have preferably previously been exposed to an antigen, by exposing the said cells to a stimulatory agent, preferably a peptide which comprises at least one antigenic determinant of said antigen. The cells may also be exposed to a CD28 stimulatory binding agent, either alone or in combination with the antigenic peptide. In preferred embodiments, the method may be used for treatment or prophylaxis of a disease characterized by a pathogenic immune or autoimmune response. The invention also provides a system for inhibiting sCTLA-4 secretion by T cells. | 04-30-2009 |
20090214596 | Nasal Vaccine - The present invention provides a nasal vaccine capable of intranasally inducing an effective immunity reaction. Specifically, the invention provides a nasal vaccine containing a compound having an NKT cell-activating action, particularly a compound represented by the formula (I): | 08-27-2009 |
20090214597 | NON-INJECTION IMMUNOTHERAPY - Methods and compositions are disclosed for the reduction of immune responses to an exogenous allergen. The reduction is obtained by pre-treatment or pre-conditioning, without injection, of a subject with the allergen so as to reduce immune responses in the subject upon additional exposure to the allergen. The invention is advantageously used in a variety of contexts, including seasonal allergies wherein pre-treatment or pre-conditioning is performed before the onset of the seasonal allergy. | 08-27-2009 |
20090285859 | Allergenic proteins of natural rubber latex, their production and use in assays - This invention relates to allergenic proteins of natural rubber latex in substantially purified form, their production and their use, together with monoclonal antibodies developed against those allergenic proteins, in assays for the qualitative and quantitative determination of the levels of the allergenic proteins in natural rubber latex or in products made from latex. Assays for identifying and/or quantitating antibodies in blood or blood products that mediate the occurrence of an allergic reaction induced by natural rubber latex are also provided, together with in vivo and in vitro diagnostic tests for detecting hypersensitivity to natural rubber latex and which involve use of the aforesaid allergenic proteins. The invention also provides for the use of the aforesaid allergens as de-sensitising agents in the treatment of latex protein allergy. There is still further provided a method for removing allergenic proteins from latex products. | 11-19-2009 |
20090297563 | Diagnosis And Treatment of Immune-Related Diseases - The present invention relates to association of one or more polymorphisms located in the human SFRS8, CD83, SLAMF1, CD86, HRH1, IL2, TLR7, TLR8 and TLR10 genes to the occurrence of allergic diseases such as rhinitis, asthma, and atopic dermatitis, auto-immune diseases, infectious diseases, and graft/host incompatibilities. The invention relates both to methods for diagnosing a predisposition to said diseases, classifying said diseases and to methods and compositions for treating subjects with said diseases. Furthermore the invention relates to screens for identifying compounds effective in treating said diseases. The invention describes specific single nucleotide polymorphisms the presence of which in the genome of an individual is strongly associated with the predisposition of said individual to an immune related disease. | 12-03-2009 |
20090297564 | Use of a Liquid Allergy Vaccine Formulation for Oromucosal Administration - The present invention relates to the use of an allergen for the manufacture of a liquid vaccine formulation for preventing or treating allergy in a subject by oromucosal administration in a dosage regimen comprising no up-dosing. | 12-03-2009 |
20090304752 | HYPOALLERGENIC VARIANTS OF THE MAJOR ALLERGEN FROM BETULA VERRUCOSA POLLEN - The invention provides hypoallergenic variants of Bet v 1 major allergen from | 12-10-2009 |
20090324650 | Method for The Production of Hydrolyzed Allergen - A method for the production of a purified extract of natural allergens comprising the steps of
| 12-31-2009 |
20100003286 | PHARMACEUTICAL PRODUCT COMPRISING TISSUE OF THE MALE VEGETAL REPRODUCTIVE SYSTEM - The present invention discloses pharmaceutical products useful for the treatment of allergies, autoimmune diseases, vaccination of mammals, as well as for in vitro diagnostics. These products preferably comprise pollen grains having altered protein composition by means of genetic modification in the plant that produces them. The production process of the present invention comprises the cultivation of genetically modified plants capable of producing pollen grains having modified molecular composition. | 01-07-2010 |
20100086568 | MODIFICATION OF ALLERGENS - The invention relates to a process for modifying allergens to enhance their suitability in immunotherapy. The invention further relates to the modified allergens and pharmaceutical compositions thereof, as well as to their use in immunotherapy. | 04-08-2010 |
20100086569 | USE OF A FIRST HOUSE DUST MITE GROUP 2 ALLERGEN FOR TREATING ALLERGY TO A SECOND HOUSE DUST MITE GROUP 2 ALLERGEN - The present invention relates to the use of a Der f 2 allergen composition for the manufacture of a vaccine for preventing or treating allergy to Der p 2, as well as to the use of a Der p 2 allergen composition for the manufacture of a vaccine for treating allergy to Der f 2. | 04-08-2010 |
20100104606 | ALLERGEN FRAGMENTS - The present invention relates to a peptide derived from the ragweed pollen allergen Amb a (1) and comprising (6 to 50) amino acid residues and pharmaceutical preparations comprising said peptide and uses thereof. | 04-29-2010 |
20100129409 | Novel Prostate Kallikrein Allergen - Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs. | 05-27-2010 |
20100158955 | Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity - The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies. | 06-24-2010 |
20100166804 | METHODS - The present invention relates to methods of prophylactically treating, reducing, delaying or controlling severe allergic reaction, e.g., to food and/or | 07-01-2010 |
20100183681 | METHOD OF TREATING ALLERGIES USING TGF-BETA1 AND ALLERGENS - The invention provides an allergy prevention method or treatment method, diets and oral drugs enabling prevention/treatment of allergic symptoms without trouble such as systemic adverse reaction, immune deficiency and the like caused by transdermal/intravenous administration of TGF-β. The allergy prevention method or treatment method is to orally administer 100 μg/kg or more of transforming growth factor-beta (TGF-β) relative to a weight of an administration target body and thereby selectively suppress Th2 immune response, while with respect to the diets and oral drugs, the content is set to contain an effective amount of transforming growth factor-beta (TGF-β) therein. | 07-22-2010 |
20100183682 | METHOD OF TREATING ALLERGIES USING TGF-BETA1 AND ALLERGENS - The invention provides an allergy prevention method or treatment method, diets and oral drugs enabling prevention/treatment of allergic symptoms without trouble such as systemic adverse reaction, immune deficiency and the like caused by transdermal/intravenous administration of TGF-β. The allergy prevention method or treatment method is to orally administer 100 μg/kg or more of transforming growth factor-beta (TGF-β) relative to a weight of an administration target body and thereby selectively suppress Th2 immune response, while with respect to the diets and oral drugs, the content is set to contain an effective amount of transforming growth factor-beta (TGF-β) therein. | 07-22-2010 |
20100247577 | TR1 CELLS, MESENCHYMAL STEM CELLS AND USES THEREOF - The present invention relates to compositions comprising Tr1 cells and mesenchymal stem cells and methods for treating an autoimmune disease, an allergic disease or an inflammatory disease. | 09-30-2010 |
20100247578 | CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF - The invention relates to a novel organosilicon carrier system for biological agents that is produced via a simple, stable and reproducible preparation process that is capable of maintaining tertiary protein structure and biological activity of the proteins and/or other biological agents in the mixture, whereby the carrier system is obtainable by mixing one or more organosilicon compounds, selected from the group comprising organosilicon, sugar organosilicon, amino sugar organosilicon compounds, their derivatives, salts and/or the vesicles formed from them, with one or more biological agents, selected from the group comprising antigens, preantigens, antigen conjugates, antibodies, pre-antibodies, antibody conjugates, allergens, allergen extracts, nucleic acids, plasmids, proteins, peptides, pharmaceutical agents, immunologically active substances and/or cosmetics, in solution at a pH value between 7 and 8, preferably 7.4, followed by homogenisation or sonication of the mixture, followed by sterile filtration of the mixture, followed by lyophilisation. | 09-30-2010 |
20100255039 | INDUCTION OF TOLERANCE TO EGG PROTEINS - The use of enzymatically hydrolysed egg proteins with a degree of hydrolysis between 15 and 28% in the manufacture of a composition for induction of oral tolerance to egg proteins in a mammal. | 10-07-2010 |
20100260805 | PEPTIDE FOR VACCINE - The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy. | 10-14-2010 |
20100291155 | ALLERGY VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION - The present invention relates to an allergy vaccine composition for mucosal administration comprising a cysteine protease allergen in a reduced active state or in an oxidised inactive state, The inventions further relates to an adjuvant system for use in a vaccine for mucosal administration comprising a cysteine protease. | 11-18-2010 |
20100297188 | ALLERGENS AND ALLERGOIDS FROM BEE VENOM - The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitisation (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterised in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterised by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy. | 11-25-2010 |
20100303866 | IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS - The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides. The present invention also provides for compositions comprising said peptides. | 12-02-2010 |
20100303867 | A COMPOSITION COMPRISING A NOTCH LIGAND AND AN ALLERGENB OR ALLERGEN BYSTANDER ANTIGEN - A method is provided for reducing an immune response to an allergen or antigenic determinant thereof in a mammal by administering a modulator of the Notch signalling pathway. | 12-02-2010 |
20100330127 | SOLUBLE AGGREGATE, IMMUNE TOLERANCE INDUCER AND MANUFACTURING METHOD THEREOF - A soluble aggregate of allergen proteins, prepared by heating multiple allergen proteins and aggregating the allergen proteins and thus enclosing the antigen structures causing allergic reactions therein. | 12-30-2010 |
20110014238 | IMMUNOGENIC PROTEIN PAS N 1 FROM BAHIA GRASS POLLEN - The present invention relates generally to novel recombinant polypeptides of Bahia grass pollen and to genetic sequences encoding same. More particularly, the present invention is directed to Pas n 1 polypeptides and derivatives, and fragments thereof and genetic sequences encoding same. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications including, but not limited to, applications in the context of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to the Bahia grass pollen. | 01-20-2011 |
20110052639 | ALLERGEN MUTANTS - Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are mutants of naturally occurring allergens. The overall α-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof. | 03-03-2011 |
20110052640 | HYPOALLERGENIC HYBRID PROTEINS OF MAJOR GROUP 1 AND 2 MITE ALLERGENS FOR USE IN THE TREATMENT OF ALLERGIES - The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from | 03-03-2011 |
20110070267 | PACKAGED VIRUS-LIKE PARTICLES FOR USE AS ADJUVANTS: METHOD OF PREPARATION AND USE - The invention relates to the finding that virus like particles (VLPs) can be loaded and packaged, respectively, with DNA oligonucleotides rich in non-methylated C and G (CpGs). If such CpG-VLPs are mixed with antigens, the immunogenicity of these antigens are dramatically enhanced. In addition, the T cell responses against the antigens are especially directed to the Th1 type. Surprisingly, no covalent linkage of the antigen to the VLP is required; it is sufficient to simply mix the VLPs with the adjuvants for co-administration. In addition, it was found that VLPs did not enhance immune responses unless they were loaded and packaged, respectively, with CpGs. Antigens mixed with CpG-packaged VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases. | 03-24-2011 |
20110097361 | METHOD OF INDUCING TOLERANCE TO AN ALLERGEN - The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention. | 04-28-2011 |
20110104209 | DNA SEQUENCE, AND RECOMBINANT PREPARATION OF THE GRASS POLLEN ALLERGEN LOL P4 - The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies. | 05-05-2011 |
20110177128 | IMMUNOTHERAPY COMPOSITIONS AND METHODS OF TREATMENT - Provided are compositions that include one or more natural, recombinant and/or modified allergens; with a pharmaceutically acceptable non-aqueous solvent to form an immunotherapy composition that includes the active ingredient and solvent, wherein the immunotherapy composition is formulated for administration to a subject in need of immunotherapy. The solvent is miscible with water and interstitial fluid. The at least one active ingredient is soluble in the solvent and insoluble in water and in an aqueous phase of interstitial fluid. The present compositions may be administered to a patient for example, as part of an immunotherapy regimen to help induce a state of immunologic tolerance to one or more allergies, or as treatment for an autoimmune disease. Also provided are methods of making such compositions. Further provided are methods that include administering the composition to a mammal. | 07-21-2011 |
20110200641 | MINOR ALLERGEN CONTROL TO INCREASE SAFETY OF IMMUNOTHERAPY - The invention discloses a method for standardizing allergen extract with respect to the contents of major as well as minor allergens. The method comprises determining relative amounts of allergens in a given extract, followed by an adjustment of the contents of major an minor allergens so as to meet predefined limitations. Also disclosed is an anti-allergy kit comprising means for profiling an allergic subject and an extract or series of extracts prepared according to the invention. | 08-18-2011 |
20110217334 | HYPOALLERGENIC MOLECULES - The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues in the region of amino acids 100 to 125 of Bet v Ia or its corresponding region of the allergen having at least 40% identity to Bet v Ia. | 09-08-2011 |
20110229523 | MODIFICATION OF ALLERGENS FOR IMMUNOTHERAPY - The present invention relates to pharmaceutical compositions for immunotherapy, for example for immunotherapy of peanut allergy. Further, the present invention relates to methods for the preparation of the present pharmaceutical compositions for immunotherapy, and their use in immunotherapy. | 09-22-2011 |
20110236426 | PHARMACEUTICAL PRODUCT FOR UP-DOSING OF ALLERGY VACCINE - This invention relates to the use of a pharmaceutical product comprising allergen and optionally an adjuvant for fast up-dosing in connection with allergy vaccination wherein a reduced number of injections are used. The invention also relates to the pharmaceutical product as such. | 09-29-2011 |
20110243993 | Method for diagnosing and creating immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments - A method is provided for diagnosis and induction of immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments, based on knowledge of the role that keratinocytes play in these ailments and is of importance for several conditions, including but not limited to allergic contact dermatitis (ACD), drug hypersensitivity reactions (DHRs) and autoimmune diseases. | 10-06-2011 |
20110243994 | STABILIZED PHARMACEUTICAL COMPOSITION, LIQUID PREPARATION OF STABILIZED PHARMACEUTICAL COMPOSITION, FILM-FORM PREPARATION, AND METHOD FOR PRODUCING FILM-FORM PREPARATION - The present invention provides a stabilized pharmaceutical composition that enables the production of a preparation for desensitization therapy useful as an agent for the prevention or treatment of allergic diseases such as pollen hypersensitivity, has outstanding allergen protein stability, and is useful for storage and transfer. | 10-06-2011 |
20110293665 | Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes - The present invention concerns a method for producing a recombinant | 12-01-2011 |
20110300182 | NUCLEIC ACID DRUG FOR TREATMENT OF ALLERGIC DISEASE - This invention provides double-stranded (ds) RNA capable of suppressing the expression of STAT6 related to allergic diseases mediated by Th2-type cytokines via RNA interference and a pharmaceutical composition for prevention or treatment of allergic diseases comprising such dsRNA. Such dsRNA is a double-stranded RNA (dsRNA) molecule targeting mRNA of the STAT6 gene composed of (a) or (b): (a) a sense strand identical to a sequence having 15 to 50 continuous nucleotides in the STAT6 gene sequence represented by SEQ ID NO: 1 or 3 and an antisense strand comprising a nucleotide sequence complementary to the nucleotide sequence of the sense strand; or (b) a sense strand comprising a sequence derived from the sequence comprising 15 to 50 continuous nucleotides of the STAT6 gene sequence represented by SEQ ID NO: 1 or 3 by deletion, substitution, or addition of 1 or several nucleotides and capable of hybridizing to the STAT6 gene and an antisense strand comprising a nucleotide sequence complementary to the nucleotide sequence of the sense strand. | 12-08-2011 |
20110311590 | COMPOSITIONS FOR TREATING AN ALLERGIC OR ASTHMATIC CONDITION - Compositions including human Tr1 cells directed to an allergen associated to an allergen or asthmatic provided the allergen is not a food allergen and use thereof for treating an allergic or asthmatic condition, excluding a food allergic condition. | 12-22-2011 |
20120058147 | Geographically Region Specific Allergy Immunotherapy for Companion Animals - Implementations and techniques for providing geographically region specific allergy immunotherapy for companion animals are generally disclosed. | 03-08-2012 |
20120070460 | DENDRITIC CELL MODULATORY MOLECULE - The present invention provides a dendritic cell modulatory molecule which modulates, and preferable inhibits, the differentiation and maturation of mammalian dendritic cells. The invention also provides pharmaceutical compositions comprising the dendritic cell modulatory molecule and homologues and active fragments thereof, antibodies thereto and methods of treatment and screening methods which utilise such molecules. | 03-22-2012 |
20120076825 | PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF - The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f). | 03-29-2012 |
20120076826 | Recombinantly Produced Allergens - The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy. | 03-29-2012 |
20120114699 | Allergoids Derived from Allergens - Modified allergens having reduced allergenicity compared to corresponding native allergenic material, wherein all or a part of the primary amine groups of the lysine and arginine residues of the allergenic molecules are functionalized and the modified allergens have the structure | 05-10-2012 |
20120121648 | RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES - Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-α. | 05-17-2012 |
20120141536 | USE OF AN ADJUVANTED ALLERGY VACCINE FORMULATION FOR PARENTERAL ADMINISTRATION - The present invention relates to the use of a seasonal allergen composition for the manufacture of a vaccine formulation for preventing or treating allergy to the allergen composition in a subject by parenteral administration, wherein the vaccine formulation is administered in a dosage regimen comprising an up-dosing phase, wherein the up-dosing phase partly or wholly overlaps with the allergen season of the allergen composition. | 06-07-2012 |
20120148626 | REDUCTION OF IN VITRO GENOTOXICITY OF POLLEN EXTRACTS BY REMOVAL OF FLAVONOIDS - The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts. | 06-14-2012 |
20120207788 | HYPOALLERGENIC HYBRID POLYPEPTIDES FOR THE TREATMENT OF ALLERGY - The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides. | 08-16-2012 |
20120258140 | RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES - Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-α. | 10-11-2012 |
20120288526 | DNA SEQUENCE AND PREPARATION OF GRASS POLLEN ALLERGEN PHL P4 BY RECOMBINANT METHODS - The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies. | 11-15-2012 |
20120288527 | ANTIALLERGIC AGENT - An agent having antiallergic effects is provided, which is easily produced and ingested. A solvent extract of green soybean is used as an antiallergic agent. A solvent extract of green soybean having the effect of suppressing IgE production and the effect of shifting the Th1-Th2 balance to the Th1 side is useful as an antiallergic agent. | 11-15-2012 |
20120294893 | EDIBLE JELLY-FORM COMPOSITION, JELLY-FORM PREPARATION AND METHOD FOR PRODUCING JELLY-FORM PREPARATION - The present invention aims to provide a jelly (as a result, easy-to-swallow), intraorally soluble edible jelly composition although it is preferably free of water. The present invention relates to an edible jelly composition including: a gelling agent; and a nonvolatile organic solvent compatible with the gelling agent. | 11-22-2012 |
20120294894 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME - An object of the present invention is to provide a pharmaceutical composition that allows stable storage and delivery of heat-labile allergens. The present invention provides a pharmaceutical composition containing: an allergen; and at least one selected from the group consisting of an organic acid salt, an inorganic acid salt, and a pH adjuster. | 11-22-2012 |
20120321665 | COMPOSITIONS AND METHODS FOR TREATING AIRWAY INFLAMMATORY DISEASES - A composition for treating an airway inflammatory disease having high molecular weight, crosslinked hyaluronan and at least one aeroallergen is provided. A method of inducing immune tolerance to one or more aeroallergens in a mammalian subject suffering from or at risk of developing an airway inflammatory disease, and a method of treating a human subject suffering from or at risk of developing an airway inflammatory disease or condition of the lungs are also provided. | 12-20-2012 |
20130045232 | MUCOSAL VACCINES - A mucosal vaccine producing an antigen-specific mucosal IgA and a blood IgG in the levels capable of exerting an effective immune induction and an infection-preventing effect, which comprises:
| 02-21-2013 |
20130058974 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing CD8+ T cell immune responses, as well as related compositions and methods. | 03-07-2013 |
20130058975 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE ANTIBODY RESPONSES - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing undesired humoral immune responses, as well as related compositions and methods. | 03-07-2013 |
20130058976 | ALLERGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS FOR ALLERGY THERAPY - Disclosed are allergen-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 03-07-2013 |
20130058977 | COMPOSITIONS AND METHODS RELATED TO INDUCED TOLEROGENIC DENDRITIC CELLS EXTERNALLY LOADED WITH MHC CLASS I-RESTRICTED EPITOPES - Disclosed are induced tolerogenic dendritic cells (itDCs) produced by combining itDCs with externally loadable MHC Class I-restricted epitopes, as well as related compositions and methods. | 03-07-2013 |
20130058978 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR INDUCING REGULATORY B CELLS - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate regulatory B cells, as well as related compositions and methods. | 03-07-2013 |
20130064854 | METHODS OF TREATING ALLERGIES WITH SUBSTANTIALLY PHENOL-FREE CARRIERS - A method for treating a patient suffering from allergy by desensitizing the patient to an allergen component that includes orally, sublingually, or intranasally administering to the patient a therapeutically effective amount of an immunomodulating composition and successively repeating the administration at a selected interval with the therapeutically effective amount of each successive administration comprising an increasing amount of the allergen component. The composition includes an amount of the allergen component that is sufficient to impart an immune response and a pharmaceutically acceptable carrier that is at least substantially free of phenol. The successive repeating occurs a sufficient number of times to reduce patient sensitivity to the allergen component, and avoids or minimizes oral adverse effects. An immunomodulating product is also described. | 03-14-2013 |
20130089572 | Partially Hydrolyzed Casein-Whey Nutritional Compositions For Reducing The Onset Of Allergies - The present disclosure relates to methods of reducing the onset of allergies. In certain embodiments, the method includes administering to an infant a nutritional composition that includes a fat or lipid source, a carbohydrate source, a protein source comprising whey and casein proteins and, optionally, a probiotic. In certain embodiments, the whey:casein ratio in the protein source is from about 50:50 to about 70:30 and the degree of hydrolysis of the proteins included in the protein source is from about 4% to about 10%. | 04-11-2013 |
20130101624 | LINEAR IGE PEPTIDE EPITOPES OF HAZELNUT ALLERGEN COR A 1 AND CELERY ANTIGEN API 1 - Linear polypeptide epitopes of hazelnut cor a 1 and celery api 1.0101 allergen of a sequence length of ten to fifteen amino acids for treatment and prevention of hazelnut or celery allergy are provided. Means and methods for diagnosing hazelnut or celery allergy, and for detecting hazelnut or celery allergens in a sample, are also provided. | 04-25-2013 |
20130142830 | Tolerogenic Plasmacytoid Dendritic Cells Co-Expressing Cd8-Alpha And Cd8-Beta And Methods Of Inducing The Differentiation Of Regulatory T Cells Using Same - This invention discloses an unexpected discovery that plasmacytoid dendritic cells (pDCs) may be segregated into immunogenic or tolerogenic species based on novel biomarkers discovered herein. Exemplary biomarkers include CD8α | 06-06-2013 |
20130156812 | Composition of Antigen and Method of Sublingual Administration - A method of sublingually administering an effective amount of an antigenic composition to a mammal in order to produce a mucosal and systemic immune response. | 06-20-2013 |
20130177594 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME - The present invention provides a pharmaceutical composition capable of preserving and delivering an allergen having poor thermal stability without using gelatin as a stabilizer, and a method for producing the pharmaceutical composition. The present invention provides a pharmaceutical composition containing an allergen and additives selected from at least two groups from among group (A) consisting of polysaccharides having high formability; group (B) consisting of mono- to hexasaccharides, sugar alcohols thereof, maltodextrin, and polyvinylpyrrolidone; and group (C) consisting of viscous polysaccharides; wherein the additives have a stabilizing effect on the allergen. | 07-11-2013 |
20130216581 | Carbon Nanotube Compositions and Methods of Use Thereof - Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy. | 08-22-2013 |
20130216582 | SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN - The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided. | 08-22-2013 |
20130224251 | VARIANTS OF GROUP 6 ALLERGENS OF THE TRUE GRASSES HAVING REDUCED ALLERGENEITY DUE TO MUTAGENESIS OF PROLINE RESIDUES - The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes. | 08-29-2013 |
20130280302 | PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF - The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f). | 10-24-2013 |
20130295139 | ADJUVANT COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES TO POLYNUCLEOTIDE-BASED VACCINES - The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE. | 11-07-2013 |
20130295140 | TESTOSTERONE OLFACTION - A composition of an olfactory stimulus mechanism for stimulating the production of testosterone. A method of increasing the level of testosterone in an individual by smelling the truffle extract, causing androgens in the truffle extract to attach to the olfactory bulb in the individual, and inducing testosterone production. A method of preventing the onset of Alzheimer's disease in an individual by the individual smelling the truffle extract, and inducing testosterone production in the individual. A method of treating symptoms of menopause in a woman by the woman smelling the truffle extract, and inducing testosterone production in the woman. A method of treating andropause in a man by a man smelling the truffle extract, and inducing testosterone production in the man. | 11-07-2013 |
20130302374 | Methods And Compositions For Dosing Of Allergens - The present invention comprises methods and compositions for immunotherapy. An aspect of the invention comprises administration of one or more allergens in compositions via oral and sublingual routes. Allergen compositions are administered in dosing intervals wherein the increase in the one or more allergens administered to the patient are provided in increasing volumes of a single concentration of at least one allergen. | 11-14-2013 |
20130302375 | MODULATION OF ANTIGEN IMMUNOGENICITY BY ADDITION OF EPITOPES RECOGNIZED BY NKT CELLS - The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination. | 11-14-2013 |
20130344112 | DETECTION OF AN IMMUNE RESPONSE - Provided herein are methods of detecting and/or monitoring the presence or severity of an immune disorder in a subject, including detecting a frequency of a Th2a subset of CD4+ T cells in a biological sample of the subject. In some embodiments, the detecting includes: (a) detecting a frequency of CD4+ T cells in a biological sample of said subject; (b) detecting a frequency of a Th2a subset of the CD4+ T cells in the biological sample; and (c) comparing the frequency of the Th2a subset with the frequency of the CD4+ T cells. | 12-26-2013 |
20140004152 | MILK-BASED PROTEIN HYDROLYSATES AND INFANT FORMULAE AND NUTRITIONAL COMPOSITIONS MADE THEREOF | 01-02-2014 |
20140010845 | SUPPRESSION OF A HYPERSENSITIVITY IMMUNE RESPONSE WITH UNRELATED ANTIGEN DERIVED FROM ALLERGEN SOURCE MATERIAL - The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen. | 01-09-2014 |
20140037690 | ANTI-ALLERGIC SUBSTANCE, ANTI-ALLERGIC AGENT, AND FOOD - This invention provides an anti-allergic substance that effectively inhibits allergic symptoms by inhibiting production of the IgE antibody associated with the development of allergies. Anti-allergic substances, pharmaceutical products (i.e., anti-allergic agents), and food (i.e., food with health-promoting benefits) containing strawberry-derived glyceraldehyde-3-phosphate do not cause side effects such as those caused by steroids, and such substances can be consumed through daily meals and can alleviate allergic symptoms. | 02-06-2014 |
20140093541 | TREATMENT FOR PEANUT ALLERGY - The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2 mg, 5 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years. | 04-03-2014 |
20140105932 | MULTIVALENT [BETA] - 1 - 2 - LINKED MANNOSE OLIGOSACCHARIDES AS IMMUNOSTIMULATORY COMPOUNDS AND USES THEREOF - This invention relates to synthetic oligo- or multivalent beta-1-2-linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell-mediated immune responses. | 04-17-2014 |
20140112955 | BIOMARKERS OF IMMUNOTHERAPY EFFICACY - The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy. | 04-24-2014 |
20140186403 | PEPTIDE FOR VACCINE - The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy. | 07-03-2014 |
20140234376 | Substituted Benzoazepines as Toll-Like Receptor Modulators - Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease. | 08-21-2014 |
20140255449 | DOSAGE OF DNAK - A pharmaceutical preparation for subcutaneous injection comprising
| 09-11-2014 |
20140271721 | PEANUT FORMULATIONS AND USES THEREOF - The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy. | 09-18-2014 |
20140271722 | ALLERGEN DOSAGE FORM - The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided. | 09-18-2014 |
20140328881 | HYPOALLERGENIC VARIANTS OF PHL P 5, THE MAJOR ALLERGEN FROM PHLEUM PRATENSE - Disclosed are hypoallergenic variants of PhI p 5, the major allergen from | 11-06-2014 |
20140363470 | PHARMACEUTICAL FORMULATIONS AND THE USE THEREOF FOR THE TREATMENT OF PEANUT ALLERGY - The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy. Specifically, the present invention relates to pharmaceutical compositions comprising a modified whole peanut extract and pharmaceutically acceptable diluents and/or excipients, wherein said modified whole peanut extract is a reduced and subsequently alkylated whole peanut extract, preferably a whole defatted peanut extract comprising soluble peanut kernel proteins such as Ara h1, Ara h2 and Ara h6. | 12-11-2014 |
20140377310 | METHODS TO TREAT ALLERGIC CONDITIONS - Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3. | 12-25-2014 |
20140377311 | METHOD OF PREVENTING ALLERGIES - The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies. | 12-25-2014 |
20150024007 | LONG TERM DISEASE MODIFICATION USING IMMUNOSTIMULATORY OLIGONUCLEOTIDES - The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification. | 01-22-2015 |
20150071967 | Tolerisation-Inducing Composition - The present invention relates to a composition comprising a tolerogenic peptide and a GSK-3 inhibitor and uses thereof. The invention also relates to the use of a GSK-3 inhibitor to accelerate the peptide-mediated shift in secretion profile of lymphocytes from pro-inflammatory to anti-inflammatory cytokines. The GSK-3 inhibitor may be used to enhance antigen-specific immunotherapy. | 03-12-2015 |
20150086593 | Allergy Inhibitor Compositions And Kits And Methods Of Using The Same - Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a | 03-26-2015 |
20150086594 | ANTI-ALLERGIC MEDICAMENT - The present disclosure relates to a method for the treatment of allergic conditions. In said method the allergens to which an individual is susceptible is identified as per the allergy profile and accordingly a formulation having potentized dispersions of each of the identified allergens is administered to the individual for a predetermined period and at a predetermined potency. The present disclosure also relates to a formulation which is a mixture of potentized dispersions of each of the identified allergens and the method of preparation for the same. The present disclosure further relates to a kit consisting of at least one allergen, at least one vehicle and accessories which include bottles and mixing sticks. | 03-26-2015 |
20150098969 | ALTERNARIA PEPTIDES - Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the | 04-09-2015 |
20150140040 | METHODS OF DEPOSITING PARTICLES OF A SUBSTANCE IN A TISSUE - Provided herein are methods of populating a target tissue of interest of a subject with particles of a substance of interest by precipitation. Example methods include administering a solution to a subject, the solution including the substance of interest and a pharmaceutically acceptable solvent. The substance of interest must be soluble in a pharmaceutically acceptable, water-miscible solvent but insoluble in tissue fluids of the target tissue of interest; and the pharmaceutically acceptable solvent must be freely miscible with the tissue fluids of the target tissue of interest. According to example embodiments, the solution is administered in a volume of the pharmaceutically acceptable solvent that will be diluted by tissue fluids in the target tissue of interest following administration at a rate that will result in precipitation of an effective amount of particles of the substance of interest in a range of sizes that will accomplish a purpose for which the substance is administered. Examples of the present methods include administering the solution to tissue of an animal, such that the substance of interest in the solution precipitates and provides an effective amount of insoluble particles of the substance of interest to the tissue. Also provided are kits that include the solution or components thereof; and methods of making such solutions. | 05-21-2015 |
20150297641 | ALLERGY TREATMENT USING ACID TREATED AQUEOUS WHEY PROTEIN EXTRACT - The invention relates to manufacture of whey protein extracts, to infant formula and to reducing or preventing food allergy. The whey protein extract is produced from a whey protein-containing composition by contacting a whey protein-containing composition with an aqueous solution to form a sample including a soluble protein-containing component and an insoluble component; recovering the soluble protein-containing component from the sample; and acidifying the soluble protein-containing component, thereby producing the whey protein extract. Extracts produced by the method of the invention may be used in infant formula, as a dietary supplement or foodstuff. | 10-22-2015 |
20160106831 | BEVERAGE COMPOSITIONS AND OTHER FORMULATIONS FOR TREATING ALLERGIES AND METHODS FOR MAKING THE SAME - A composition for preventing and/or alleviating an allergy related condition and methods of making such compositions are disclosed herein. A composition in accordance with a particular embodiment can include honey having pollen derived from a known plant species and/or from a known geographic location. The composition can also include a herbal and/or vitamin supplement, wherein the supplement has an anti-inflammatory property. The composition can be in liquid form, such as suitable for drinking, or in a powdered form suitable for reconstitution in liquid. | 04-21-2016 |
20160116470 | DETECTION OF AN IMMUNE RESPONSE - Provided herein are methods of detecting and/or monitoring the presence or severity of an immune disorder in a subject, including detecting a frequency of a Th2a subset of CD4+ T cells in a biological sample of the subject. In some embodiments, the detecting includes: (a) detecting a frequency of CD4+ T cells in a biological sample of said subject; (b) detecting a frequency of a Th2a subset of the CD4+ T cells in the biological sample; and (c) comparing the frequency of the Th2a subset with the frequency of the CD4+ T cells. | 04-28-2016 |
20160185831 | NUCLEIC ACIDS FOR TREATMENT OF ALLERGIES - The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs. | 06-30-2016 |
20180020712 | BABY FOOD PRODUCTS CONTAINING ALLERGENIC PROTEINS AND METHODS OF DELIVERING SAME | 01-25-2018 |